Cell Therapeutics cancer news

Cell Therapeutics amended its shareholder rights plan. Under the new plan, each preferred stock right, which expires Dec. 3, 2015, entitles the holder to purchase an additional share of common stock at $8. The rights previously expired on Jan. 7, 2013, and entitled the holder to purchase additional shares at $14. Cell Therapeutics could not be reached for details. ...